State Street Corp Tcr2 Therapeutics Inc. Transaction History

State Street Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.0 - $1.62 $27,900 - $45,198	27,900 Added 25.52%	137,219 $205,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $2.94 $873,198 - $1.22 Million	-413,838 Reduced 79.1%	109,319 $317,000
Q1 2022 May 16, 2022	BUY	$2.4 - $4.71 $19,123 - $37,529	7,968 Added 1.55%	523,157 $1.44 Million
Q4 2021 Feb 14, 2022	SELL	$4.58 - $8.34 $4.58 Million - $8.34 Million	-999,528 Reduced 65.99%	515,189 $2.4 Million
Q3 2021 Nov 15, 2021	SELL	$8.44 - $18.35 $6.05 Million - $13.1 Million	-716,507 Reduced 32.11%	1,514,717 $12.9 Million
Q2 2021 Aug 16, 2021	BUY	$16.41 - $24.71 $703,496 - $1.06 Million	42,870 Added 1.96%	2,231,224 $36.6 Million
Q1 2021 May 17, 2021	BUY	$20.38 - $34.07 $24.7 Million - $41.3 Million	1,211,294 Added 123.97%	2,188,354 $48.3 Million
Q4 2020 Feb 16, 2021	BUY	$19.0 - $32.63 $11.8 Million - $20.2 Million	619,597 Added 173.33%	977,060 $30.2 Million
Q3 2020 Nov 10, 2020	BUY	$13.1 - $20.69 $1.29 Million - $2.04 Million	98,780 Added 38.19%	357,463 $7.26 Million
Q2 2020 Aug 14, 2020	BUY	$6.51 - $16.85 $361,487 - $935,646	55,528 Added 27.33%	258,683 $3.97 Million
Q1 2020 May 11, 2020	BUY	$6.01 - $16.01 $1.22 Million - $3.25 Million	203,155 New	203,155 $1.57 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.